OBJECTIVES: Bankruptcy may be a particular concern for cancer patients. Costs from treatment and supportive care, along with non-medical costs such as lost income, can be financially devastating. We estimated the incidence of bankruptcy following cancer diagnosis using linked cases from the Washington SEER registry with Western District of Washington bankruptcy court records. METHODS: Cancer cases (age Ͼ20) were identified for 1995-2009. Our analyses were limited to patients reporting their first primary cancer, excluding cancers in situ or diagnosed at time of death. To determine the proportion of cancer cases reporting personal bankruptcy (Chapter 7 or 13) following cancer diagnosis, we generated cumulative incidence (CI) of bankruptcy, to allow for the competing risk of death. We calculated CI using Gray's method to compare bankruptcies among different cancers. RESULTS: There were Nϭ231,799 cancer cases; after a mean follow-up of 4.3(sdϭ4.1) years, Nϭ4805 (2.1%) had filed for bankruptcy after cancer diagnosis. Average age at diagnosis of filers was 52.8(sdϭ13.6) years and 55% were female compared to 63.9(sdϭ14.6) years and 49% female for all cancer cases (pϽ0.0001 for both comparisons). Mean and median time to bankruptcy was 3.3 and 2.5 years, respectively. At 1, 2 and 3 years following diagnosis, the proportion of bankruptcies filed was 23%, 41%, and 56%, respectively. By 3 years, the incidence of bankruptcy was 1.3%. Thyroid cancer had the highest CI at 3 years (2.7%), followed by uterine (1.7%), melanoma (1.6%), breast (1.6%), leukemia/lymphoma (1.4%), colorectal (1.2%), lung (1%) and prostate (0.9%); the CI for all other cancers was 1.3%. The overall CI of bankruptcy was 3.3%. CONCLUSIONS: Two in 100 patients file for bankruptcy following a cancer diagnosis. Thyroid and uterine cancer have the highest incidence of bankruptcy. Factors associated with bankruptcy following cancer are yet to be determined.
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INJECTION OF LONG-ACTING SOMATOSTATIN ANALOGS: A COST CONSEQUENCE ANALYSIS IN FRANCE, GERMANY, THE UNITED KINGDOM AND THE UNITED STATES
Roze S 1 , Kurth H 2 , Maury le Breton A 2 1 HEVA, Lyon, France, 2 IPSEN, Boulogne Billancourt, France OBJECTIVES: Patients treated for neuroendocrine tumors and acromegaly have to be periodically injected with a long-acting somatostatin analog (SSA). This study aimed at evaluating the economic implications of using a new pre-filled device for Somatuline Autogel/Depot versus Sandostatin LAR. The study was performed in three European countries and the US. METHODS: A quantitative study was performed in France, Germany, the UK and the US, including 77 nurses. The majority of nurses were from hospital wards, specialized in endocrinology and oncology. The number of SSA patients per nurse was at least 3 per year. Time spent for each injection and number of clogging episodes was recorded per nurse and per type of injection (Somatuline new device or LAR). Cost of successful injection was calculated per patient / per nurse using retail costs for the 4 countries. RESULTS: With LAR, 2 clogging incidents were reported. This led to an average of 79 injections for LAR vs. 77 for Somatuline new device. The calculated cost per successful injection for the 4 countries pooled together was in Euro: 1'603 and 1'628 respectively for Somatuline new device and LAR. The incremental cost between the 2 treatments was EUR 25 per injection. Assuming an 85% compliance, this translated up to EUR 255 per patient per year. When considering only the 3 European countries, the annual difference was EUR 724. CONCLUSIONS: The usage of a new pre-filled Somatuline device for the injection of SSA could lead to substantial savings for hospitals and health-care payers. Due to the differences in retail prices across countries, these savings could potentially be even more significant in Europe. $366,376) . We also observed substantial variation across racial subgroups in the probability of chemotherapy being cost-effective given various willingness-to-pay thresholds per LYG. Results were similar in sensitivity analysis. CONCLUSIONS: Chemotherapy use in elderly M1 PC patients is associated with an ICER of $99,146 per LYG in our sample. Subgroup analysis revealed racial heterogeneity in ICER point estimates and considerable statistical uncertainty. In order to generate a reliable evidence base for personalized medicine, efforts to increase the representation of minorities in clinical trials, registries, and other health care datasets need to continue. 
PCN55 RACIAL VARIATION IN THE COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PROSTATE CANCER
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COST-EFFECTIVENESS OF TEMSIROLIMUS FOR METASTIC RENAL-CELL CARCINOMA AND POOR PROGNOSIS PATIENTS IN MEXICO
OBJECTIVES:
Renal cell carcinoma (RCC) is the most common primary renal malignant neoplasm in adults. It accounts for approximately 90% of renal tumors and 2% of all adult malignancies. The purpose of this study was to estimate the costeffectiveness of temsirolimus versus interferon-␣ for patients treated as first line with metastatic renal-cell carcinoma and poor prognosis from an institutional perspective. METHODS: A three-state Markov model was performed to estimate health and economic consequences during a time horizon of 12 months (six-week cycles). Effectiveness measures were: overall survival, progression-free survival (months), and quality adjusted life years gained (QALYs). Drug safety was also assessed (grade 3-4 adverse events-AE). Transition probabilities were obtained from a meta-analysis collecting international published literature data. Doses of comparators were: temsirolimus (25mg/week) and interferon-␣ (41,380,000 IU/ week). Resource use was obtained from Social Security Mexican Institute hospital records (nϭ154). Costs were extracted from institutional sources and include: hospitalization, drugs, medical procedures, laboratory tests and adverse events management. Probabilistic sensitivity analyses were performed and acceptability curves were constructed. RESULTS: Temsilorimus overall survival resulted in 10.9 months (CI 95% 10.63 -11.17) and interferon-␣ achieved 7.3 months (7.09 -7.51) (pϽ0.05). For progression-free survival, temsirolimus estimation was 5.5 months (5.36 -5.64) and interferon-␣ exhibited 3.1 months (3.01 -3.19) (pϽ0.05). Lastly, temsirolimus raised QALYs in 0.74 (0.72 -0.76), (pϽ0.05), and diminished grade 3-4 hematologic AE in Ϫ9.59% (Ϫ9.35% -Ϫ9.83%), (pϽ0.05). Incremental cost-effectiveness ratio (ICER) for overall survival and progression-free survival for temsirolimus against interferon-␣ were US$4,839 [US$4,718-US$4,961] and US$7,259 [US$7,077-US$7,441], respectively. The ICER using QALYs resulted in US$23, 458 [US$22, 046] . Probabilistic sensitivity analyses showed that results were robust. CONCLUSIONS: Regarding overall survival, progression-free survival and QALYs temsirolimus represents a cost-effective therapy in Mexican patients who suffer metastatic renal-cell carcinoma and poor prognosis.
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ECONOMICS OF A MULTI-GENE ASSAY TO PREDICT RECURRENCE OF EARLY STAGE BREAST CANCER: EXPERIENCE OF A LARGE UNITED STATES INSURANCE PROGRAM
Hornberger J 1 , Chien R 1 , Kreb K 2 , Hochheiser LI 2 1 Cedar Associates LLC, Menlo Park, CA, USA, 2 Humana, Inc., Louisville, KY, USA OBJECTIVES: National guidelines recommend a 21-gene Recurrence Score (RS) to aid in adjuvant treatment decision in estrogen-receptor-positive, node-negative early stage breast cancer (ERϩ, LN-ESBC) patients. To assess the economic implication of the assay in community practices from the perspective of an US payer. METHODS: Analysis of 952 women with ESBC enrolled with Humana, Inc. (Louisville, KY) tested with the 21-gene RS between June, 2006 and June, 2010. The proportion of women classified by the assay by RS risk categories, utilization and costs of chemotherapy regimens, and supportive care, and costs of adverse events were obtained from Humana. We adapted a validated Markov model to compute the cost implications of RS for a representative patient. The probability of risk of recurrence, chemotherapy benefits and decision impact of RS were derived from published studies. RESULTS: 255 patients within the tested population received adjuvant chemotherapy. Adjuvant chemotherapy was administered to 10% of women at low risk, 36% of women at intermediate risk, and 72% of women at high risk of recurrence. Based on a meta-analysis in the reduction of chemotherapy after RS, the model estimated an average per patient test saving of $1,115. The immediate direct savings for chemotherapy drug, supportive care, and management of adverse events were $1,897, $2,593, $475, respectively. Prevention of recurrence through appropriate treatment of high-risk patients resulted in additional saving of $126. CONCLUSIONS: The adoption of the 21-gene RS lead to targeted management of women with ERϩ, LN-ESBC, and consequently save direct medical costs.
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IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR ER؉ HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-EFFECTIVE?
Djalalov S 1 , Beca J 1 , Hoch J 2 1 St. Michael's Hospital, Toronto, ON, Canada, 2 Cancer Care Ontario, Toronto, ON, Canada OBJECTIVES: Approximately 60% of breast cancer cases are a type sensitive to hormones. Tamoxifen is the most widely used treatment of hormone-dependent breast cancer. The pharmacological activity of tamoxifen is dependent on its conversion by the hepatic drug-metabolizing enzyme CYP2D6. Patients with reduced A164 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
